HIGHLIGHTS
- What: Our analysis suggests that while both fremanezumab and eptinezumab are likely effective in reducing MMDs, both eptinezumab groups were able to reduce MMDs more than either fremanezumab-treated groups.
- Who: Sultan Akbar from the ATStill University, School of Osteopathic Medicine in Arizona (ATSU-SOMA). have published the Article: A Comparison of Fremanezumab and Eptinezumab in the Prevention of Chronic Episodic Migraine, in the Journal: (JOURNAL)
- Future: For this review seemed to have a greater reduction of disease activity than did Further studies with greater sample sizes are needed to conclude which has . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.